Background: Mast cells (MCs) crucially contribute to many inflammatory diseases. However, the physiological controls preventing excessive activities of MCs in human skin are incompletely understood. Objective: Since endocannabinoids are important neuroendocrine MC modifiers, we investigated how stimulation/ inhibition of cannabinoid 1 (CB1) receptors affect the biology of human skin MCs in situ.
In many developed countries, the incidence of allergic diseases is increasing to epidemic proportions, affecting up to 30% of the population. 1 Thus, these diseases constitute a considerable burden to affected patients and to health-care providers. Given the crucial role that mast cells (MCs) play in the pathogenesis and clinical phenotype of allergic diseases and many other chronic inflammatory disorders, 2, 3 we clearly need a better understanding of how healthy human tissues that are very rich in MCs (such as skin or bronchial mucosa) avoid excessive activities and numbers of MCs under physiological circumstances. 4 This should open new, more effective, and better-tolerated avenues to counteracting the critical input of MCs into allergic and many other chronic inflammatory diseases.
As key protagonists of innate immunity, MCs not only play a pivotal role in anti-infection defense and ''danger''-response systems but also regulate inflammation, tissue repair, and tissue remodeling. [2] [3] [4] [5] [6] Although it is now understood that MCs are involved in both inciting and limiting inflammation, 3, [7] [8] [9] the main focus of clinically applied MCs research still is on undesired, excessive activities of MCs and their disease-promoting consequences, for example, in atopic eczema, chronic urticaria, allergic asthma, and allergic rhinitis. Yet, the physiological controls of MCs that prevent an excessive accumulation and activation within normal human tissues have been much less studied and are therefore only very incompletely understood. Thus, it remains a major unmet challenge for translational MC research to identify important endogenous controls that prevent excessive activation and numbers of MCs within healthy human tissues (as opposed to cell culture conditions, where behavior of MCs is generally studied in the-highly artificial-absence of complex regulatory cues that normally emanate from their local tissue environment). Therefore, these endogenous controls are best studied under in situ conditions. In the human system, they can best be characterized in human skin, since the latter is easily accessible, is very rich in MCs 10 and becomes frequently available during elective plastic surgery. It is important to remember that immature bone marrowderived MC progenitors are deposited not only in peripheral tissues, such as skin, where they complete their development, 2, 3 but mature skin MCs can also be generated in situ from resident progenitor cells in the absence of bone marrow, namely, in the stroma of organ-cultured murine and human hair follicles (HFs), the follicular connective tissue sheath (CTS). 11, 12 Therefore, we hypothesized that robust mechanisms must be in place to avoid excessive increases in MC numbers by limiting the intracutaneous maturation of MCs from resident progenitor cells within human skin, namely, from resident, CTS-associated MC progenitors. 11, 12 Given the pivotal dependence of MCs on signals from their local tissue milieu, 2, 6, 9 it is critical to elucidate the behavior of normal primary human MCs within their natural tissue environment. In this context, neuroendocrine controls of MCs are of particular interest since neuromediators regulate multiple human skin MC functions, for example, during innate immune defense, neurogenic inflammation, angiogenesis, wound healing, and hair growth. 9, 11, 13 Moreover, the maturation of human CTS-MCs from resident precursors and/or their activation are strongly stimulated by prototypic stress-associated mediators, namely, by corticotropin-releasing hormone 12, 14 and substance P. 15 Thus, the organ culture of healthy, adult human scalp HFs with their MC-rich CTS 12, 15 provides an unconventional, but highly instructive, accessible, and physiologically and clinically relevant human model system for studying primary skin MCs, intracutaneous MC progenitors, and their neuroendocrine controls within a precisely defined mesenchymal compartment in situ.
Besides their multiple functions in the nervous system, endocannabinoids are now recognized as important neuroendocrine regulators of MC biology. [16] [17] [18] [19] The endocannabinoid system (ECS) consists of cannabinoid (CB) receptors, their endogenous ligands (ie, endocannabinoids, such as anandamide [AEA] and 2-arachidonoylglycerol), and enzymes responsible for endocannabinoid synthesis and degradation. 16, [20] [21] [22] [23] However, the role of the ECS in the regulation of primary human MCs in general, and of human skin MCs in situ in particular, remains unknown. Moreover, there are several conflicting reports on how CB stimulation affects rodent or human MC lines in vitro (for details, see this article's introductory section in the Online Repository at www.jacionline. org). Furthermore, it remains to be studied whether the ECS affects MC maturation from human progenitor cells in situ.
Therefore, we investigated whether and how CB stimulation/ inhibition affects normal, experimentally unmanipulated human skin MCs in situ. 24 Specifically, we asked whether resident MCs in the CTS of HFs express functional CB1 and whether the local ECS regulates their activation and/or maturation from resident progenitor cells.
METHODS

HF organ culture
Human scalp HFs in the anagen VI stage of the hair cycle 25, 26 were microdissected and organ cultured as described previously. 12, 15, 24 Human tissue collection and handling were performed according to the Helsinki guidelines, following Institutional Research Ethics approval (University of L€ ubeck) and informed patient consent. In total, 414 anagen VI HFs were isolated from excess normal occipital and temporal scalp skin obtained from 8 healthy patients (aged 49-72 years, average, 59 years) undergoing routine face-lift surgery. HF organ-culture details are given in this article's Methods section in the Online Repository at www.jacionline.org.
Mast cell histochemistry
Mature human skin MCs were detected with 2 sensitive histochemical staining methods: toluidine blue and Leder's esterase histochemistry.
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Quantitative immunohistochemistry
Kit, CB1, tryptase, chymase, and FcεRIa antigens were immunodetected in situ by using the highly sensitive tyramide signal amplification technique (Perkin Elmer, Boston, Mass) according to the manufacturer's protocol and were assessed by quantitative immunohistomorphometry with the help of Image J (National Institutes of Health, Bethesda, Md) in precisely defined reference areas (for details, see this article's Methods section in the Online Repository). 
CB1 knockdown in situ
Statistical analysis
Data were analyzed by using either the Mann-Whitney U test or the Student t test for unpaired samples, with the use of Prism 4.0 software (GraphPad Prism Program, GraphPad, San Diego, Calif). P values of <.05 were regarded as significant. All data in the Figures showing quantitative data are expressed as means 6 SEM.
RESULTS
Human CTS-MCs express CB1
Human scalp HFs, including their MC-rich CTS, express CB1 mRNA and protein, but not CB2. 21 Therefore, we first asked whether cells positive for Kit (CD117, a marker that identifies even relatively immature MCs 6, 12, 27 ) within the CTS 12, 15 (which does not contain any Kit1 melanocytes) express CB1. By using immunohistology it was found that 75.5% of Kit1 CTS-MCs prominently coexpressed CB1, both in organ-cultured HFs (Fig 1, A and B ) and in intact human scalp skin (Fig 1, C) . The highly CB1-selective fluorescent ligand Tocrifluor T1117 bound directly to Kit1 CTS-MCs (Fig 1, D) , demonstrating that these CB1 receptors display functional and specific binding activity.
CB1 inhibition induces the activation of CTS-MCs and increases their number
We then assessed whether treatment with the prototypic endocannabinoid AEA (30 mM) 16, 22, 24 or with the selective CB1 agonist arachidonyl-2-chloroethylamide (ACEA; 30 mM) 28 altered the total number of histochemically detectable CTSMCs and/or their activation status (degranulation). Interestingly, this was not the case (Fig 2, In contrast, the diarylpyrazole derivative and selective CB1 antagonist/inverse agonist AM251 (1 mM) 16, 24 significantly increased both the number of mature CTS-MCs and their degranulation (Fig 2, B-E, and Fig E1, A and B) . These effects were completely abrogated by coincubation with AEA or ACEA (Fig 2, B-E, and Fig E1, A and B) . High-resolution light microscopy independently confirmed that selectively antagonizing CB1 significantly upregulated the degranulation of CTS-MCs ( Fig  E1, D and E) . By transmission electron microscopy, we found that AM251-treated MCs showed the typical ultrastructural morphology of degranulated human MCs 29 ( Fig E1, F) . Thus, antagonizing CB1-mediated signaling clearly increases the degranulation of human skin MCs in situ. This conflicts with a previous report that the CB1 antagonist AM281 does not affect the degranulation of RBL-2H3 cells by itself.
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CB1 inhibition induces the maturation, but not proliferation, of CTS-MCs Next, we studied the impact of CB1 stimulation/inhibition on the number of Kit1 cells. In human skin mesenchyme, Kit is expressed almost exclusively by MCs, and Kit immunohistology allows visualization of both more immature MCs and mature MC populations than is possible with classical MC histochemistry, which depends on the demonstration of metachromatic granules. 2, 12, 15 Surprisingly, CB1 inhibition upregulated the number of Kit1 human CTS-MCs in situ (Fig 3, A-C ) (since we cannot exclude that CB12 but Kit1 CTS-MCs were also counted, particularly in the control group, the real effect of CB1 blockade on CTS-MCs may well be even more significant than is apparent from Fig 3, B and C) . Interestingly, however, AM251 altered neither the number of Ki671/Kit1 cells (Fig  3, D) nor of terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling1/Kit1 cells (Fig 3, F) . Most Kit1 CTS cells were Ki672 in both control and AM251-treated organ-cultured HF (Fig 3, E) . This suggests that the increased number of Kit1 CTS-MCs seen after CB1 inhibition does not The number of degranulated (B and C) and total CTS-MCs (D and E) per visual field in 1-day cultured HFs with AEA (30 mM), ACEA (30 mM), and AM251 was analyzed. *P < .05, **P < .01, and ***P < .001 denote significant differences for the indicated comparisons. ACEA, Arachidonyl-2-chloroethylamide; AM251, CB1 receptor antagonist/inverse agonist.
primarily result from stimulating the proliferation or inhibiting the apoptosis of resident MCs. Although no statistically significant differences in the number of Ki671/Kit1 cells were seen between test and control groups, it cannot be ruled out that the availability of a larger number of human HFs for study might have revealed a slight, significant difference. However, it is unlikely that this would explain the large differences seen in the total number of histochemically and immunohistologically detectable MCs during such a short HF organ-culture period (24 hours).
To independently validate this concept, we assessed the expression of antigens characteristically found on/in mature MCs, that is, the MC proteases tryptase and chymase and the high-affinity receptor for IgE, FcεRIa. 2, 6, 27, 31 Indeed, multiple cells positive for tryptase, FcεRIa, or chymase were detected in the CTS of organ-cultured HFs, and their number was significantly increased by AM251 treatment (Fig 3, G-I ).
This suggests that CB1 blockade, rather than affecting the proliferation/apoptosis 4 of resident mature CTS-MCs, first, stimulates the differentiation of resident, highly immature, Kit2 MC progenitors into Kit1 MCs, and subsequently promotes their differentiation into fully mature tryptase1/chymase1/FcεRIa1 MCs (note that in our organ-culture assay, MC precursors could not possibly have been recruited from the circulation or bone marrow, even though these resident MC progenitors may well have immigrated from the bone marrow into the HF-CTS in utero and/or postnatal life). Thus, constitutive CB1 stimulation is required to avoid the excessive intracutaneous maturation of functional MCs from resident progenitor cells within healthy human skin.
CB1 gene knockdown is possible in organ-cultured human HFs
To further probe this novel and provocative concept by experimentally reducing the possibility of endocannabinoids to signal via CB1, CB1 gene silencing was attempted by standard siRNA technology. Successful knockdown was demonstrated by a significant downregulation of CB1 immunoreactivity (Fig 4, A and B; see Fig E2 , A, in this article's Online Repository at www.jacionline.org) as well as by quantitative PCR (which demonstrated a reduction in the intrafollicular CB1 transcript level; data not shown). Additional functional evidence that CB1 knockdown was successful arose from the MC effects reported below.
Continuous CB1 stimulation by endocannabinoids controls the number and activation of human CTS-MCs in situ
CB1 knockdown significantly increased the number of CTS-MCs that were detectable by either histochemistry or immunohistology (Kit1, tryptase1) and increased their degranulation. The CTS of CB1 siRNA-treated human HFs contained greater numbers of mature, degranulated MCs than did the CTS of HFs treated with scrambled oligos (Fig 5, A-E, H and I). Interestingly, Kit immunoreactivity also significantly increased in the CTS of CB1 knockdown HFs (Fig 5, F) . CB1 knockdown decreased intracellular (see Fig E3, B, in this article's Online Repository at www.jacionline.org) but increased intercellular tryptase immunoreactivity ( Fig E3, A and C) . This suggests that tryptase was actively secreted after CB1 knockdown. However, CB1 knockdown did not significantly elevate tryptase levels in the culture medium (Fig E3, D) , possibly because of the wellrecognized strong binding of secreted tryptase to collagen. 32 In fact, many extracellularly located, tryptase1 granules were detectable in the collagen-rich CTS, most prominently in CB1 siRNA-treated HFs (Fig E3, A) . CB1 gene knockdown did not stimulate CTS-MC proliferation in situ (Fig 5, G) .
Taken together, this suggests that, under physiological conditions, continuous CB1 stimulation by endocannabinoids, which are present in substantial quantities within the CTS of normal human scalp HFs, 24 maintains Kit expression and numbers/activation of MCs at a relatively low baseline level. These CB1-silencing data further support the concept that CB1 blockade stimulates the maturation of very immature, resident MC precursors in situ that are not yet Kit1. These then differentiate first into Kit1 and subsequently into tryptase1/chymase1/FcεRIa1 mature MCs.
Endocannabinoids inhibit excessive activation of MCs via CB1
Since excessive degranulation and numbers of MCs in human skin play a key role in the pathogenesis and clinical phenotype of several major skin diseases, 2,3,7,9 we asked whether CB1 stimulation counteracts the MC-activating effects of classical MC secretagogues. Quantitative MC histomorphometry in situ demonstrated that this is the case: Both the potent nonselectively CB1-stimulating endocannabinoid AEA (30 mM) 21, 24 and the CB1-specific agonist, the synthetic cannabinoid ACEA (30 mM) 21, 28 inhibited the degranulation-promoting effects of key endogenous and exogenous MC activators: substance P (10 210 mol/ L), a key mediator of stress-induced, neurogenic skin inflammation 14, 33 (Fig 6, A) , and the standard secretagogue compound 48/80 (10 mg/mL) 34 (Fig 6, B) . Thus, CB1 stimulation effectively counteracts excessive activation of MCs in normal human skin in situ. This suggests that rather than acting on resting MCs (see Fig  2, B-E, and Fig E1, A and B) , the ECS of the human skin may primarily tone down activated MCs in situ.
CB1 stimulation regulates the maturation of human CTS-MCs by controlling stem cell factor expression by the HF epithelium Human HF epithelium expresses functional CB1 24 and is a major source of stem cell factor (SCF), 12 the key growth factor that drives the maturation of MCs.
3,6 Therefore, we asked whether CB1 stimulation/inhibition may induce the observed effects on the maturation and activation of MCs indirectly through stimulating the intrafollicular expression of SCF by CB11 HF epithelial cells in situ. An intact human scalp skin sample was used as a positive control for SCF immunohistochemistry (see Fig E4 in this article's Online Repository at www.jacionline.org).
Indeed, AM251 (1 mM) significantly upregulated SCF expression in organ-cultured HFs both at the gene level (Fig 7, C) and at the protein level (Fig 7, A and B) . This was abrogated by coadministering ACEA (30 mM) (Fig 7, B and C) . Furthermore, AM251 significantly increased SCF secretion into the culture medium of outer root sheath keratinocytes in vitro (Fig 7, D) . After AM251 treatment, compared with the control, SCF immunoreactivity was prominently detectable in proximity to the cell membrane (Fig 7, E) . Sixty percent of the cells treated with AM251 showed this fluorescence staining pattern, whereas this was observed in only 36.8% of the cells in the vehicle control group. This further suggests increased SCF secretion after blockade of CB1-mediated signaling and adds additional credence to the concept that SCF production by human HF epithelium is controlled by the ECS via CB1 stimulation.
To further assess this indirect effect of CB1 inhibition by AM251 on CTS-MCs via SCF secretion by the HF epithelium, 11, 12 we performed additional HF organ culture for 1 day with 1 mM of AM251 in the presence of 1 mg/mL of SCFneutralizing antibody. When test and control groups were compared with respect to the number of Kit1 CTS-MCs, the increase in the number of Kit1 MCs after pharmacological CB1 blockade was partially, yet significantly, reduced by neutralizing SCF (Fig 7, F) .
CB1 deletion induces maturation and activation of CTS-MCs in vitro
Finally, by examining CB1 knockout (KO) mice, 35, 36 we probed whether the novel concepts revealed above in an organcultured human skin appendage in situ also apply in vivo. As expected, c-kit1 CTS-MCs were CB12 in these KO mice (see Fig  E5 in this article's Online Repository at www.jacionline.org). Moreover, in line with our human HF organ-culture data, the total Quantitative immunohistomorphometry of CB1 immunohistochemistry with CB1 siRNA-treated human HFs. **P < .01 and ***P < .001 denote significant differences for the indicated comparisons. ORS, Outer root sheath; SCR, scrambled siRNA treated HFs; TFE, transfection reagent treated HFs.
keratinocytes. White arrow denotes Kit1/Ki67-cells. F, Quantitative immunohistomorphometry of Kit/TUNEL double1 cells. Quantitative immunohistomorphometry of FcεRIa (G), tryptase (H), and chymase (I)1 cells. *P < .05, **P < .01, and ***P < .001 denote significant differences for the indicated comparisons. ACEA, Arachidonyl-29-chloroethylamide; AM251, CB1 receptor antagonist/inverse agonist; NS, not significant; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling. (Fig 8, A,  C, and D) . Here, the number of degranulated MCs was also significantly higher than in age-and hair cycle-matched wild-type mice (Fig 8, B) . There was no significant change in the number of Ki67/ Kit double1 CTS-MCs between CB1 KO and wild-type mice (Fig 8, E) . This suggests that even in vivo, CB1 acts primarily on murine skin MC maturation and activation and not at the level of MC proliferation. Taken together, these complementary murine data suggest that constitutive CB1 stimulation is also required in vivo to avoid excessive maturation and activation of skin MCs.
DISCUSSION
Collectively, our findings provide the first unequivocal evidence that within their natural tissue habitat, normal human skin MCs utilize CB1-mediated signaling to limit not only their own activation/degranulation but also their maturation from resident progenitor cells in situ. We show that CB1 stimulation/blockade has both direct and indirect (ie, SCF-mediated) effects on normal human skin in situ.
Previous in vitro studies, which had investigated rodent and human MC lines, 17, 18, 30, [37] [38] [39] [40] had painted a contradictory picture on the role of the ECS in the activation of MCs (see this article's introductory section in the Online Repository at www.jacionline. org). This may be due to the fact that MC lines of debatable physiological/clinical relevance were studied or that isolated primary MCs were investigated in the absence of crucial physiological cues from their mesenchymal and epithelial microenvironment. Here, we document that under maximally ''physiological'' in vitro conditions, continuous ''tonic'' stimulation of CB1 expressed on human skin MCs by locally produced endocannabinoids maintains the number and activities of mature MCs at a relatively low baseline level.
The indirect, SCF-mediated effects of CB1 signaling revealed here provide the first indication that tonic CB1 signaling also appears to be essential to avoid excessive SCF secretion in human skin. Since it is very well possible that the SCF-neutralizing antibody we have used here did not completely block all SCF activity (thus explaining why the effect is not completely abrogated), our assay system does not allow one to state with certainty whether all the effects of the CB1 antagonist on MCs are ''direct'' or ''indirect'' through SCF. However, our results with Tocrifluor (Fig 1, D) as well as with CB1/Kit-double immunofluorescence (Fig 1, A-C) make it reasonable to assume that direct, CB1-mediated effects on MCs operate side by side with indirect ones (ie, CB1-regulated secretion of SCF by human HF keratinocytes).
Our study demonstrates that the CTS provides an important peripheral tissue site of and source for immature MC precursors, not only in mouse vibrissae HFs 11 but also in healthy human skin. 12 Moreover, we provide the first evidence that the differentiation of these resident precursors into mature, functional MCs is constitutively inhibited by the ECS. In contrast to rapidly (1 mM) or/and SCF-neutralizing antibody (1 mg/mL). *P < .05, **P < .01, and ***P < .001 denote significant differences for the indicated comparisons. ACEA, Arachidonyl-29-chloroethylamide; AM251, CB1 receptor antagonist/inverse agonist; ORS, outer root sheath.
proliferating hair matrix keratinocytes 24 or various neuronal cell populations, 41 CB1-mediated signaling primarily seems to affect the maturation and activation of CTS-MC but not their proliferation or cell death. That this also applies to murine skin in vivo attests to the physiological relevance of human HF organ-culture.
While the CB1 KO mouse data confirm our human HF organculture observations with respect to the regulation of skin MCs by CB1, it must be kept in mind that under in vivo conditions, the MC phenomena observed in the skin of CB1 KO mice may reflect more complex mechanisms. We are currently testing how CB1 stimulation/blockade affects human mucosal-type MCs in organ-cultured human nasal polyp samples, an excellent surrogate tissue for human bronchial mucosa. 42 Our available pilot observations indicate that CB1 also suppresses the maturation of functional mucosa-type MCs from resident progenitor cells: Kit1 cells in human nasal polyps express CB1 in situ, and AM251 increases the total number of tryptase1 and Kit1 MCs without modulating their proliferation (K.S., N.Z, T.H., and R.P., manuscript in preparation). This encourages one to explore whether CB1-mediated ''tonic'' inhibition of the maturation and activation of MCs by the ECS is a general principle that also operates in other human MC populations than the ones investigated here in human skin.
Our study strongly suggests that targeting the ECS for the downmodulation of excessive MC activities in human skin could become an attractive new therapeutic strategy in clinical medicine. Moreover, the current study encourages one to systematically dissect whether allergic diseases and many other disorders characterized by excessive numbers and/or activation of MCs (eg, in bronchial asthma, allergic rhinitis, atopic eczema, prurigo dermatoses, psoriasis, mastocytosis, and chronic urticaria) are associated with defined defects in the ECS, such as insufficient endocannabinoid synthesis, excessive endocannabinoid metabolism, and/or defective CB1-mediated signaling.
Furthermore, our data call attention to the HFs' CTS as a previously ignored tissue compartment that may play an important role in excessive MC activities within inflamed, hair-bearing human skin. (We are currently examining whether similar principles apply to MCs in the stroma of other human skin appendages such as sweat and sebaceous glands.) Methodologically, we show that HF organ culture provides an excellent, clinically relevant new in situ model for preclinical MC research in the human system, whose clinical relevance exceeds the traditional analysis of isolated human MCs, MC leukemia lines, or mouse models.
Studying primary human MC biology and pathology under clinically relevant in situ conditions in human HF organ culture, thus, deserves to be fully discovered by mainstream MC research as a research tool that ideally complements and validates concepts derived from the study of MC lines and murine in vivo models. Available human skin organ-culture assays 43, 44 can complement such HF organ-culture systems so as to further probe whether selective CB1 agonists can be employed as an adjuvant strategy for the management of allergic and chronic inflammatory skin disorders with excessive accumulation and degranulation of MCs. Even though such organ-culture approaches exclude neural and perfusion-dependent inputs into skin MC biology, these 2 companion assay systems allow one to dissect the clinically important but underexplored neuroendocrine controls of skin MCs 12, 15, 16, 45, 46 under conditions where critical cell-cell (eg, MCs-fibroblast and MCs-keratinocyte) as well as cell-matrix interactions are fully preserved.
Since CB1 receptors, in vitro, may signal in the absence of ligand, 47 in theory, CB1 receptors might exert ''tonic'' MC inhibition in human skin even in the absence of endocannabinoids. Also, it deserves to be investigated whether some patients with excessive skin MC numbers and/or massive degranulation of skin MCs (eg, in atopic dermatitis or chronic urticaria) display CB1 receptor mutations or CB1 receptor polymorphisms that incapacitate this ''tonic'' inhibitory signaling system. Similar effects could be brought about in genetically susceptible individuals by insufficient intracutaneous endocannabinoid synthesis and/or excessive endocannabinoid degradation. 48 Although Paul Ehrlich himself, the discoverer of MCs, had already noted that skin MCs are found in highest density around blood vessels, nerves, and HFs, their physiological functions in these specific locations remain to be fully explored. In selected peripheral tissue sites, such as HFs, MCs have been proposed to bestow ''some low-level immune privilege'' 8 (note that HFs are immunoprivileged miniorgans 49 ). Such an immunoinhibitory role of perifollicular MCs would make it particularly important that excessive, proinflammatory MCs activation and excessive numbers of mature MCs are strictly avoided in human skin. The constitutive, inhibitory ''endocannabinoid tone'' revealed here may represent one such mechanism. Moreover, therapeutic stimulation of this inhibitory pathway offers an attractive alternative to, and complementation of, promoting MC apoptosis 4 where this is clinically desired.
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Key messages
d Endocannabinoids control not only human skin mast cell (MC) activation but also their maturation from resident progenitor cells in situ via cannabinoid 1 (CB1) stimulation.
d Endocannabinoids also regulate stem cell factor (SCF) expression in human hair follicle epithelium (increased SCF production via CB1 stimulation).
APPENDIX
There are conflicting reports on how CB stimulation affects rodent or human MC lines in vitro. For example, the CB1 and 2 agonist CP55940 and the CB1 agonist methanandamide reportedly inhibited IgE-mediated MC degranulation in the RBL-2H3 MC line in vitro. These effects were reversed by treatment with the CB1 antagonist AM281; however, administration of this CB1 antagonist alone did not affect MC degranulation.
E1 Methanandamide reportedly also inhibited IgE-mediated MC degranulation in primary murine bone marrow-derived MCs in vitro.
E2 In RBL-2H3 cells, the endocannabinoid palmitoylethanolamide produced a small, but significant reduction in antigen-stimulated serotonin release at high concentrations, whereas anandamide (AEA) did not have an effect. In contrast, the endocannabinoid 2-arachidonoylglycerol and methanandimide both increased the antigen-stimulated MC degranulation. E3 Palmitoylethanolamide, but not AEA, downmodulated MC activation via CB2 in the same cell line. E4 Furthermore, the phytocannabinoid compound cannabidiol triggered RBL-2H3 cell degranulation.
E5 D
9
-Tetrahydrocannabidol and D
8
-tetrahydrocannabidol also induced histamine release from rat peritoneal MCs in vitro, apparently in a CB1/CB2-independent manner, while endocannabinoids and their analogues neither induced histamine secretion nor promoted compound 48/80-induced degranulation. E6 Concerning human MCs, it has been reported that supernatants from SW756 cervical carcinoma cells stimulated the degranulation of the human MC line LAD2, which was inhibited by CB2 stimulation.
E7
This leaves us with a confusing and contradictory picture of the role that CB1 versus CB2 stimulation may play in the control of MC activation. Moreover, it remains completely unknown how the ECS affects primary human MCs, and under clinically relevant conditions, for example, human skin MCs in situ.
METHODS Reagents
AEA, ACEA, AM251, substance P, and compound 48/80 were purchased from Sigma-Aldrich (Taufkirchen, Germany), whereas 5-carboxytetramethylrhodamine-conjugated AM251 Tocrifluor was purchased from Tocris Bioscience (Bristol, United Kingdom).
HF organ culture
Isolated HFs were maintained in supplemented serum-free William's E medium.
E8-E11 HFs were first incubated overnight to adapt to culture conditions after which the medium was replaced and vehicle or test substances were added. For the organ-culture with MC secretagogues, substance P and compound 48/80, HFs were first treated with AEA (30 mM) or ACEA (30 mM) for 1 day after the overnight incubation. Then, the HFs were treated with either substance P (10 210 mol/L) or compound 48/80 (10 mg/mL) in combination with AEA or ACEA for an additional 1 day. Following culturing for the time indicated, HFs were then cryoembedded and prepared for histology and immunohistochemistry.
Immunohistochemistry
For the detection of Kit, CB1, tryptase, chymase, and FcεRIa, the highly sensitive tyramide signal amplification (TSA) technique (Perkin-Elmer, Boston, Mass) was applied. Cryosections were incubated overnight at 48C with primary antibodies, rabbit anti-human CD117 (Cell Marque Corp, Rocklin, Calif) at 1:1000, rat anti-mouse CD117 (BD Biosciences, San Jose, Calif) at 1:5000, rabbit anti-human CB1 (Cayman Chemical, Ann Arbor, Mich, or Santa Cruz, Calif) at 1:400, mouse anti-human FcεRIa (Acris GmbH, Hiddenhausen, Germany) at 1:1000, mouse anti-human chymase (Abcam plc, Cambridge, United Kingdom) at 1:1000, or mouse anti-human tryptase (Abcam plc) at 1:5000 diluted in TNB (Tris, NaOH, blocking reagent, TSA kit; Perkin-Elmer). Thereafter, the cryosections were incubated with goat biotinylated antibodies against rabbit or mouse IgG (Jackson Immunoresearch Laboratories, West Grove, Pa) at 1:200 in TNB for 45 minutes at room temperature (RT). The TSA method was applied according to the manufacturer's protocol. Double-immunostaining for Kit and CB1 was performed using the TSA technique. Briefly, cryosections were incubated overnight at 48C with a primary antibody against Kit followed by biotinylated goat anti-rabbit IgG (Jackson Immunoresearch Laboratories) (1:200 in TNB, 45 minutes, RT). Sections were then incubated with streptavidin-conjugated horseradish peroxidase (1:100, 30 minutes, TSA kit) and were finally incubated with fluorescein isothiocyanate-conjugated tyramide (1:50, TSA kit). After careful washing with TNT wash buffer (0.1 mol/L Trizma hydrochloride, 0.15 mol/L NaCl, and 0.05% Tween 20), sections were then incubated overnight with rabbit anti-human CB1 antibody (Santa Cruz) at 48C followed by incubation with goat biotinylated antibody against rabbit IgG (Jackson Immunoresearch Laboratories) (1:200 in TNB, 45 minutes, RT). After incubating with streptavidine-conjugated horseradish peroxidase (1:100, 30 minutes, TSA kit), sections were incubated with tetramer rhodamine-conjugated tyramide (1:50, TSA kit).
To study the proliferation of Kit1 cells, double-immunostaining for Ki-67 and Kit was performed. Briefly, after the staining for Kit by using a TSA kit, sections were incubated overnight at 48C with a mouse anti-human Ki67 antibody (DAKO, Hamburg, Germany) at 1:20 in PBS for detecting human Ki67 or with rat anti-mouse Ki67 antibody (DAKO) at 1:100 in PBS for detecting mouse Ki671 cells. Sections were then washed with PBS, followed by incubation with rhodamine-conjugated goat anti-mouse IgG or goat anti-rat IgG (Jackson Immunoresearch Laboratories) (1:200 in PBS, 45 minutes) at RT.
To evaluate the apoptosis of Kit1 cells, Kit immunostaining and terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling was performed on the same sections. Briefly, after the immunostaining for Kit, sections were incubated with a digoxigenin-deoxy-UTP (ApopTag fluorescein in situ apoptosis detection kit; Millipore Corp, Billerica, Mass) in the presence of terminal deoxynucleotidyl transferase (60 minutes) at 378C. After the incubation with Stop/Wash buffer (ApopTag kit) (10 minutes, RT) and the additional wash with PBS, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling-positive cells were visualized by an anti-digoxigenin fluorescein isothiocyanate-conjugated antibody (ApopTag kit) (30 minutes, at RT).
To evaluate the immunoreactivity of CB1 in CB1 siRNA-treated HFs as well as in intact human scalp skin sections, the expression of CB1 in the HFs was visualized by using the peroxidase-based avidin-biotin complex method (Vectastain Elite ABC kit; Vector Laboratories, Burlingame, Calif). Frozen sections were fixed in cold acetone and rinsed with PBS, and endogenous peroxidase activity was saturated with 3% H 2 O 2 in PBS for 15 minutes. After the incubation with 5% normal goat serum, sections were incubated with rabbit anti-human CB1 antibody (Cayman Chemical) (1:40 in PBS) at 48C overnight. After incubation with a biotinylated goat anti-rabbit antibody (Jackson Immunoresearch Laboratories) (45 minutes, at RT), sections were treated with Vectastain ABC reagent (Vector Laboratories) and visualized with AEC (3-amino-9-ethylcarbazol) (Vector Laboratories). As negative controls, the appropriate primary antibodies were omitted from the procedure. The specificity of CB1 immunostaining was measured on intact human scalp skin sections (Fig E2, B) and mouse brain sections (positive control), which clearly demonstrated positive CB1 immunoreactivity in the expected areas (data not shown).
For detecting SCF in organ-cultured human HFs as well as isolated human outer root sheath (ORS) keratinocytes, indirect immunofluorescence method was applied by using anti-human SCF (Acris GmbH) at 1:20 in PBS as a primary antibody and fluorescein isothiocyanate -conjugated (rhodamine for ORS keratinocytes) goat anti-mouse IgG at 1:200 in PBS as a secondary antibody. An intact human scalp skin sample was used as a positive control (Fig E4) .
The immunoreactivity of CB1, Kit, tryptase, and SCF in defined reference areas was assessed by quantitative immunohistomorphometry E9,E11-E13 by using the Image J software (National Institutes of Health, Bethesda, Md).
For counting MCs, MCs were classified as ''degranulated'' when 5 or more extracellularly located metachromatic granules could be detected histochemically at high magnification (3400) by light microscopy (visual field). The number of degranulated and total CTS-MCs around the HF per visual field was counted, and at least 13 visual fields per HF in total were evaluated.
Some degranulated MCs were detected even in the vehicle control group (Fig E1, A and B) . This is in line with previously reported data. E9 The percentage of degranulated MCs in freshly microdissected HFs evaluated by Leder'sesterase histochemistry was significantly higher than in unmanipulated human skin, suggesting that the trauma of HF microdissection caused some degree of degranulation of MCs. MCs in freshly isolated skin also displayed a steadystate level of degranulation (Fig E1, C) .
High-magnification images of Kit and CB1 double1 cell were taken by laser scanning confocal microscopy (Fluoview 300, Olympus, Tokyo, Japan) running Fluoview 2.1 software (Olympus).
High-resolution light microscopy and transmission electron microscopy
Organ-cultured human scalp HFs were immersed in a mixture containing 2% paraformaldehyde, 2.5% glutaraldehyde, and 0.025% CaCl 2 in 0.1 mol/L sodium cacodylate buffer, pH 7.4, and fixed. The specimens were then immersed in 1% osmium tetroxide in the same buffer. The samples were dehydrated in a gradient series of ethanol, immersed in propylene oxide, and embedded in plastic resin. Thin and thick sections were generated on a Leica Ultra UCT (Leica, Vienna, Austria). Thick sections (1 mm) were prepared for an alkaline-Giemsa histochemistry. E14 MCs were defined as degranulated according to the previous article. E14 Thin sections were stained with uranyl acetate and lead citrate and observed with an electron microscope (JEM-1200EXII, JEOL, Tokyo, Japan).
Quantitative PCR
Expressions of specific mRNA transcripts of SCF were analyzed by quantitative real-time PCR performed on an ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, Calif) as described before E12,E13 using TaqMan primers and probes (Assay ID: Hs00241497_m1 for human SCF). Three different internal housekeeping genesglyceraldehyde 3-phosphate dehydrogenase, b-actin, cyclophilin A-were assessed (Assay ID: Hs99999905_m1 for glyceraldehyde 3-phosphate dehydrogenase, Hs99999903_m1 for b-actin, and Hs99999904_m1 for cyclophilin A). The amount of SCF transcripts was normalized to those of the control genes as previously reported.
E12,E13 Data were analyzed using 1-way ANOVA with Bonferroni's post hoc test *P < .05, **P < .01.
CB1 knockdown in situ
All reagents required for transfection (human CB1 siRNA [sc-39910], control (scrambled, SCR) siRNA [sc-37007], siRNA transfection reagent [sc-29528] , and siRNA transfection medium [sc-36868]) were obtained from Santa Cruz. HF transfection was performed according to the manufacturer's protocol. Briefly, freshly isolated human HFs were kept in cold William's E medium right before the transfection. During transfection, CB1-specific siRNA or control siRNA (2.5 mL) and siRNA transfection reagent (2 mL) were mixed in the transfection medium (500 mL) per well (24-well plate). After the careful wash, HFs were applied to each well (3 HFs per well) and incubated at 378C in a CO 2 incubator for 6 hours after which the medium was replaced with supplemented William's E medium. HFs were cryoembedded 24 hours following transfection.
CB1 KO mice
Targeted disruption of the CB1 receptor gene was performed by replacing the CB1 coding sequence with a nonreceptor sequence by homologous recombination in MPI2 embryonic stem cells. Mutant mice have been crossed to C57BL/GJ animals for more than 13 generations and are therefore considered to be congenic for this genetic background. Homozygous CB1 2/2 mice and wild-type (CB1
) animals were generated by matings of heterozygous (CB1 1/2 ) mice.
E15,E16
Tryptase immunoassay
Organ-cultured human scalp HFs were treated with CB1 siRNA for 1 day. The culture supernatants of these HFs were collected for the analysis. The level of tryptase was measured by a fluorescent enzyme immunoassay by using a commercial assay from Phadia (ImmunoCap Tryptase, Uppsala, Sweden). The principle of the assay is based on a monoclonal antitryptase capture antibody that specifically binds tryptase. After washing, b-galactosidaselabeled antitryptase antibody is added. Bound complexes are stained by the conversion of 4-methyliumbelliferyl-b-D-galactoside. The fluorescent signal is correlated with the amount of tryptase.
Isolation and culture of ORS keratinocytes
Isolation and culture of human ORS keratinocytes were performed according to our established protocol. E17 Briefly, ORS keratinocytes were isolated by an enzymatic digestion (0.2% trypsin, 0.1% EDTA in calcium-and magnesiumfree PBS for 1 hour at 378C all from Sigma-Aldrich) and gentle trituration. Following isolation, the single-cell suspension was removed, collected by centrifugation (1000 rpm for 10 minutes), and resuspended in ORS keratinocyte culturing medium. It comprises 3:1 mixture of Dulbecco's modified Eagle medium (supplemented with L-glutamine, Na-pyruvate, 4.5 g/L glucose) and Ham's F12 (both from Invitrogen, Invitrogen Ltd, Paisley, United Kingdom), supplemented with 10% fetal clone II (Hyclone, HyClone Laboratories Inc, Logan, Utah) and 5 mg/mL insulin, 0.4 mg/mL hydrocortisone, 2.43 mg/mL adenin, 2 nM triiodothyronine, 0.1 nM cholera toxin, 10 ng/mL EGF, 1 mM ascorbyl-2-phosphate, 100 U/mL penicillin G, and 25 mg/mL gentamycin (all from Sigma). ORS keratinocytes were seeded and cultured on mitomycintreated human dermal fibroblast feeder-layer in ORS keratinocyte culturing medium.
SCF immunoassay
The supernatant of human ORS keratinocytes culture were collected and freezed at 2808C until the assay was performed. Samples were analyzed for their SCF levels by using Quantikine Human SCF ELISA Kit (R&D Systems, Abingdon, United Kingdom).
Mouse skin harvesting was performed under an appropriate animal experimentation license obtained by the University of Bonn. Human tissue use was approved by the Ethics Committee, University of L€ ubeck.
DISCUSSION
Our results show that CB1 blockade affects MCs not only directly but also induces SCF secretion by human HF keratinocytes. This suggests that, under physiological conditions, ''tonic'' CB1 stimulation by the intracutaneous ECS maintains SCF production by human HF epithelium at a relatively low level and that blocking CB1 releases this endogenous ''molecular brake'' on SCF production. Increased SCF secretion then serves as a stimulus for the intracutaneous maturation of MCs from resident precursors in the CTS. These data not only provide the first available evidence for a link between CB1 signaling and SCF biology but also underscore the importance of epithelialmesenchymal interactions in human skin MC biology. Do ECS affect itching as well as tissue remodeling after inflammation? This important question has been discussed in a number of original reports and reviews, including our own.
E18,E19
Given the limitations of our organ-cultured human HF system, which is unsuitable for pruritus research, evidently, we cannot provide any corresponding experimental data with this assay on how the ECS may affect itch (pruritogenic pruritus) and its processing in the central system after inflammation. For this, CB1 KO mice are a more appropriate model.
However, a couple of relevant reports on the effects of endocannabinoids on itch already suggest that the ECS may indeed play an important role in itch. For example, topical application of the endocannabinoid N-palmitoylethanolamine, to patients with mild to moderate atopic eczema significantly reduced the intensity of erythema, pruritus, excoriation, scaling, lichenification, and dryness. E20 Since the inhibition of AEA-degrading enzymes (such as fatty acid amide hydrolase [FAAH] ) increases AEA levels in mice, E21,E22 it is interesting to note that FAAH KO mice or FAAH inhibitor-treated mice show significant reduction in scratching without affecting locomotor behavior. E23 Moreover, excessive mast cell activity is well recognized to play a key role in many itch-associated skin diseases, including allergy and atopic dermatitis, and neurogenic skin inflammation. E24-E26 Therefore, our current data are well in line with the concept that the ECS may also modulate MC-dependent pruritogenic pruritus via reducing MC degranulation and via avoiding excessive MC maturation from resident intracutaneous progenitor cells. Moreover, since not only HF and epidermal melanocytes E27 but also rapidly proliferating hair matrix keratinocytes prominently express Kit on the gene and protein levels (see Peters et al E28 ), it is conceivable that CB1-regulated changes in the secretion of the cognate ligand (SCF) could also have an on the growth and remodeling of selected, Kit-expressing epithelial cell populations in the HF, besides direct effects of (endo-)cannabinoid on CB11 HF epithelial cells. 
